A Phase 3 interventional study of Febuxostat and Febuxostat in Gout, sponsored by Takeda. Completed at 258 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2012-02-02.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing febuxostat in Gout — 1 open to participants now, 1 under way, none of them phase 3. Febuxostat · Gout.
Among the 29 studies testing febuxostat in Gout, this one has the largest enrollment, is the only one that started in 2007, is one of 10 in phase 3, and was the 6th registered.
347 studies on the registry are indexed under Gout; 49 are open to participants now.
Browse Gout studies →1 of the 29 studies testing febuxostat in Gout is open now. Recruiting first, the newest first:
Haiphong University of Medicine and Pharmacy
Healthy volunteers
Febuxostat: first FDA approval 2009 (ULORIC), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,269 is above the median of 83 across 286 interventional studies indexed under Gout.
Median enrollment 109 across the 29 interventional studies. Of the 27 that completed or were terminated, 18 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 29 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
15 studies in Gout by Takeda: none open now, none under way, none of them phase 3. Of 15 finished, 14 (93%) have results posted.
Among the 15 studies in Gout by Takeda, this one has the largest enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2007, is one of 6 in phase 3, and was the 8th registered.
Takeda’s Gout studies by the year they started, since 2001.
1 of the studies testing febuxostat in Gout that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07369622Haiphong University of Medicine and PharmacyHLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness | 2027-06-20 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies testing febuxostat in Gout, from their registry updates:
Among Takeda’s 15 in Gout:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy and safety of febuxostat, once Daily (QD), to allopurinol in subjects with hyperuricemia and gout.
Renal impairment is common in subjects with gout, with the prevalence ranging from 50% to 70%. This population represents an unmet medical need as uricosuric drugs are contraindicated in these patients, and the only available treatment, allopurinol, may have to be dose reduced to avoid overt side effects.
Febuxostat (TMX-67) is a non-purine selective xanthine oxidase inhibitor being developed as an orally administered agent for management of hyperuricemia in patients with gout.
Treatment duration will be 6 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Febuxostat
Drug: Febuxostat
(dependent on renal function)
Drug: Allopurinol
Febuxostat 40 mg, capsules, orally, once daily for up to 6 months.
Also known as: TMX-67, Tei-6720, Uloric
Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.
Also known as: TMX-67, Tei-6720, Uloric
Allopurinol 200 mg or 300 mg, capsules, orally, once daily for up to 6 months. Dose is dependent on the subject's renal function. Subjects with normal renal function or mild renal impairment received 300 mg once daily; subjects with moderate renal impairment received 200 mg once daily.
Also known as: Zyloprim
Percentage of Subjects Whose Serum Urate Level is <6.0 Milligrams Per Deciliter (mg/dL) at the Final Visit.
The percentage of subjects whose serum urate level was \<6.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate value was collected.
Time frame: Last Visit on treatment (up to 6 months)
Percentage of Renal Impairment Subjects Whose Final Visit Serum Urate Level is <6.0 mg/dl
The percentage of subjects with mild-to-moderate renal impairment whose serum urate was \<6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected.
Time frame: Last Visit on treatment (up to 6 months)
Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 2 Visit.
Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 2 visit was summarized.
Time frame: Month 2
Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 4 Visit.
Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 4 visit was summarized.
Time frame: Month 4
Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 6 Visit.
Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 6 visit was summarized.
Time frame: Month 6
Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 2 Visit.
Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was \<5.0 mg/dL at the Month 2 visit was summarized.
Time frame: Month 2
Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 4 Visit.
Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was \<5.0 mg/dL at the Month 4 visit was summarized.
Time frame: Month 4
Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 6 Visit.
Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was \<5.0 mg/dL at the Month 6 visit was summarized.
Time frame: Month 6
Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Final Visit.
The percentage of subjects whose serum urate level was \<5.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate values was collected.
Time frame: Last Visit on treatment (up to 6 months)
Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 2 Visit
Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was \<4.0 mg/dL at the Month 2 visit was summarized.
Time frame: Month 2
Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 4 Visit
Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was \<4.0 mg/dL at the Month 4 visit was summarized.
Time frame: Month 4
Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 6 Visit
Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was \<4.0 mg/dL at the Month 6 visit was summarized.
Time frame: Month 6
Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Final Visit
The percentage of subjects whose serum urate level was \<4.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate values was collected.
Time frame: Last Visit on treatment (up to 6 months)
Mean Percent Change From Baseline in Serum Urate Levels at Month 2 Visit.
Serum urate values were obtained at the Month 2 visit. The percent change in serum urate from baseline to the Month 2 visit was summarized.
Time frame: Baseline and Month 2
Mean Percent Change From Baseline in Serum Urate Levels at Month 4 Visit
Serum urate values were obtained at the Month 4 visit. The percent change in serum urate from baseline to the Month 4 visit was summarized.
Time frame: Baseline and Month 4
Mean Percent Change From Baseline in Serum Urate Levels at Month 6 Visit.
Serum urate values were obtained at the Month 6 visit. The percent change in serum urate from baseline to the Month 6 visit was summarized.
Time frame: Baseline and Month 6
Mean Percent Change From Baseline in Serum Urate Levels at Final Visit.
The percent change in serum urate from baseline to the Final visit was summarized. The final visit was the last visit at which a serum urate value was collected.
Time frame: Baseline and Last Visit on treatment (up to 6 months)
Subjects were enrolled at 324 sites in the United States from 16 February 2007 to 12 March 2008.
| Milestone | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Allopurinol 200 mg or 300 mg QD |
|---|---|---|---|
| Started | 757 | 756 | 756 |
| Completed | 632 | 598 | 621 |
| Not completed | 125 | 158 | 135 |
| Withdrew: Adverse event | 49 | 61 | 64 |
| Withdrew: Protocol violation | 10 | 2 | 4 |
| Withdrew: Personal reasons | 12 | 24 | 9 |
| Withdrew: Lost to follow-up | 28 | 33 | 28 |
| Withdrew: Therapeutic failure | 1 | 1 | 1 |
| Withdrew: Withdrawal by subject | 14 | 20 | 16 |
| Withdrew: Inclusion/exclusion criteria not met | 0 | 2 | 0 |
| Withdrew: Gout flare | 3 | 7 | 2 |
| Withdrew: Reason not specified | 8 | 8 | 11 |
The percentage of subjects whose serum urate level was \<6.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate value was collected.
| percentage of subjects | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Allopurinol 200 mg or 300 mg QD |
|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Level is <6.0 Milligrams Per Deciliter (mg/dL) at the Final Visit. | 45.2 | 67.1 | 42.1 |
The percentage of subjects with mild-to-moderate renal impairment whose serum urate was \<6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected.
| percentage of subjects | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Allopurinol 200 mg or 300 mg QD |
|---|---|---|---|
| Percentage of Renal Impairment Subjects Whose Final Visit Serum Urate Level is <6.0 mg/dl | 49.7 | 71.6 | 42.3 |
Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 2 visit was summarized.
| percentage of subjects | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Allopurinol 200 mg or 300 mg QD |
|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 2 Visit. | 49.1 | 74.1 | 43.2 |
Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 4 visit was summarized.
| percentage of subjects | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Allopurinol 200 mg or 300 mg QD |
|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 4 Visit. | 47.1 | 75.2 | 45.5 |
Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 6 visit was summarized.
| percentage of participants | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Allopurinol 200 mg or 300 mg QD |
|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 6 Visit. | 48.9 | 75.3 | 46.6 |
Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was \<5.0 mg/dL at the Month 2 visit was summarized.
| percentage of subjects | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Allopurinol 200 mg or 300 mg QD |
|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 2 Visit. | 15.4 | 45.9 | 11.7 |
Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was \<5.0 mg/dL at the Month 4 visit was summarized.
| percentage of subjects | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Allopurinol 200 mg or 300 mg QD |
|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 4 Visit. | 15.0 | 51.6 | 13.5 |
Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was \<5.0 mg/dL at the Month 6 visit was summarized.
| percentage of subjects | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Allopurinol 200 mg or 300 mg QD |
|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 6 Visit. | 19.3 | 49.7 | 14.8 |
The percentage of subjects whose serum urate level was \<5.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate values was collected.
| percentage of subjects | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Allopurinol 200 mg or 300 mg QD |
|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Final Visit. | 16.5 | 44.0 | 13.2 |
Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was \<4.0 mg/dL at the Month 2 visit was summarized.
| percentage of subjects | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Allopurinol 200 mg or 300 mg QD |
|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 2 Visit | 2.1 | 17.5 | 1.5 |
Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was \<4.0 mg/dL at the Month 4 visit was summarized.
| percentage of subjects | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Allopurinol 200 mg or 300 mg QD |
|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 4 Visit | 2.0 | 18.6 | 1.4 |
Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was \<4.0 mg/dL at the Month 6 visit was summarized.
| percentage of subjects | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Allopurinol 200 mg or 300 mg QD |
|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 6 Visit | 3.1 | 20.3 | 1.8 |
The percentage of subjects whose serum urate level was \<4.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate values was collected.
| percentage of subjects | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Allopurinol 200 mg or 300 mg QD |
|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Final Visit | 2.5 | 17.5 | 1.5 |
Serum urate values were obtained at the Month 2 visit. The percent change in serum urate from baseline to the Month 2 visit was summarized.
| percent change from baseline | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Allopurinol 200 mg or 300 mg QD |
|---|---|---|---|
| Mean Percent Change From Baseline in Serum Urate Levels at Month 2 Visit. | -35.1 ± 12.8 | -44.5 ± 15.5 | -33.8 ± 13.2 |
Serum urate values were obtained at the Month 4 visit. The percent change in serum urate from baseline to the Month 4 visit was summarized.
| percent change from baseline | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Allopurinol 200 mg or 300 mg QD |
|---|---|---|---|
| Mean Percent Change From Baseline in Serum Urate Levels at Month 4 Visit | -34.9 ± 13.1 | -45.5 ± 15.6 | -34.5 ± 12.8 |
Serum urate values were obtained at the Month 6 visit. The percent change in serum urate from baseline to the Month 6 visit was summarized.
| percent change from baseline | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Allopurinol 200 mg or 300 mg QD |
|---|---|---|---|
| Mean Percent Change From Baseline in Serum Urate Levels at Month 6 Visit. | -35.6 ± 13.2 | -45.1 ± 16.0 | -34.4 ± 13.3 |
The percent change in serum urate from baseline to the Final visit was summarized. The final visit was the last visit at which a serum urate value was collected.
| percent change from baseline | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Allopurinol 200 mg or 300 mg QD |
|---|---|---|---|
| Mean Percent Change From Baseline in Serum Urate Levels at Final Visit. | -33.1 ± 15.5 | -40.6 ± 19.9 | -31.3 ± 16.2 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Febuxostat 40 mg QD | — | — | — |
| Febuxostat 80 mg QD | — | — | — |
| Allopurinol 200 mg or 300 mg QD | — | — | — |
| Event | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Allopurinol 200 mg or 300 mg QD |
|---|---|---|---|
| Cholecystitis and CholelithiasisHepatobiliary disorders | 0/757 | 0/756 | 3/756 |
| Lower Respiratory Tract and Lung InfectionsInfections and infestations | 1/757 | 1/756 | 3/756 |
| Prostatic Neoplasms MalignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/757 | 1/756 | 3/756 |
| Disturbances in Consciousness NECNervous system disorders | 0/757 | 0/756 | 3/756 |
| Cardiac Conduction DisordersCardiac disorders | 0/757 | 2/756 | 0/756 |
| Coronary Artery Disorders NECCardiac disorders | 2/757 | 0/756 | 2/756 |
| Ischaemic Coronary Artery DisordersCardiac disorders | 1/757 | 2/756 | 1/756 |
| Pain and Discomfort NECGeneral disorders | 1/757 | 2/756 | 1/756 |
| Bacterial Infections NECInfections and infestations | 1/757 | 1/756 | 2/756 |
| Non-Site Specific Injuries NECInjury, poisoning and procedural complications | 0/757 | 2/756 | 0/756 |
| Event | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Allopurinol 200 mg or 300 mg QD |
|---|---|---|---|
| Upper Respiratory Tract InfectionsInfections and infestations | 71/757 | 53/756 | 57/756 |
| Liver Function AnalysesInvestigations | 63/757 | 52/756 | 50/756 |
| Diarrhoea (Excluding Infective)Gastrointestinal disorders | 45/757 | 47/756 | 57/756 |
| Musculoskeletal and Connective Tissues Signs and Symptoms NECMusculoskeletal and connective tissue disorders | 43/757 | 38/756 | 32/756 |
| Age, Customized(subjects) | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Allopurinol 200 mg or 300 mg QD | Total |
|---|---|---|---|---|
| <45 years of age | 192 | 196 | 180 | 568 |
| 45 to <65 years of age | 450 | 432 | 445 | 1327 |
| ≥65 years of age | 115 | 128 | 131 | 374 |
| Age Continuous(years) | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Allopurinol 200 mg or 300 mg QD | Total |
|---|---|---|---|---|
| Mean | 52.5 ± 11.68 | 53.0 ± 11.79 | 52.9 ± 11.73 | 52.8 ± 11.73 |
| Sex: Female, Male(Participants) | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Allopurinol 200 mg or 300 mg QD | Total |
|---|---|---|---|---|
| Female | 35 | 46 | 47 | 128 |
| Male | 722 | 710 | 709 | 2141 |
| Ethnicity (NIH/OMB)(Participants) | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Allopurinol 200 mg or 300 mg QD | Total |
|---|---|---|---|---|
| Hispanic or Latino | 47 | 49 | 53 | 149 |
| Not Hispanic or Latino | 710 | 707 | 702 | 2119 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Allopurinol 200 mg or 300 mg QD | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 6 | 10 | 6 | 22 |
| Asian | 26 | 25 | 37 | 88 |
| Native Hawaiian or Other Pacific Islander | 11 | 10 | 11 | 32 |
| Black or African American | 83 | 78 | 67 | 228 |
| White | 620 | 618 | 625 | 1863 |
| More than one race | 11 | 15 | 8 | 34 |
| Unknown or Not Reported | 0 | 0 | 2 | 2 |
| Body Mass Index(subjects) | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Allopurinol 200 mg or 300 mg QD | Total |
|---|---|---|---|---|
| <18.5 kilograms per meter² (kg/m²) | 0 | 1 | 1 | 2 |
| 18.5 kg/m² to <25 kg/m² | 50 | 46 | 42 | 138 |
| 25 kg/m² to <30 kg/m² | 215 | 232 | 236 | 683 |
| ≥30 kg/m² | 490 | 476 | 476 | 1442 |
| Missing | 2 | 1 | 1 | 4 |
| Cardiovascular Disease(subjects) | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Allopurinol 200 mg or 300 mg QD | Total |
|---|---|---|---|---|
| No | 336 | 316 | 320 | 972 |
| Yes | 421 | 440 | 436 | 1297 |
| Renal Function(subjects) | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Allopurinol 200 mg or 300 mg QD | Total |
|---|---|---|---|---|
| Moderate Renal Impairment | 130 | 136 | 136 | 402 |
| Mild Renal Impairment | 349 | 367 | 365 | 1081 |
| Normal Renal Function | 278 | 253 | 255 | 786 |
2 further baseline measures are reported on the registry.
Showing the first 100 of 258 sites. Choose a country and city above to see the rest.
The record gives a start of Feb 2007, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2009, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Febuxostat